Phase II Dose Confirmed and Encouraging Survival Data
Phase II Dose Confirmed and Encouraging Survival Data
Midatech has today announced encouraging headline results from a Phase I study at the University of California, San Francisco (‘UCSF’) in patients with the orphan condition, Diffuse Intrinsic Pontine Glioma
Midatech has announced unaudited interim results for the six months ended 30 June 2020. These cover a period of significant transition for the Group, subsequent to which it has raised
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Drug delivery technology group Midatech Pharma (MTPH) had traders scratching their heads on Friday over the reasons for a rise of as much as 50%, as the US listing of
Zak Mir highlights USA Penny Stock Chart breakers and gives an overview of the fundamentals in this NYSE, NASDAQ video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Zak Mir highlights some of the most followed stocks on the small-cap London market and gives an overview of the fundamentals in this video charting update.
Share Talk highlighted no less than fifteen new company “52-wk high” across our social media platforms, the micro markets are healthy and delivering shareholder value. Watching the small-cap marker we
Midatech has today announced its signing of further research collaboration, this time with an unnamed ‘global pharmaceutical’ group that wishes to utilise its Q-Sphera™ platform in order to improve/optimise the
Midatech Pharma’s next generation drug delivery technologies to be applied to new modalities in collaboration with a European pharmaceutical company.